Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
Valeant Pharmaceuticals International Inc

VRX

Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International Inc historical holders

total: 14

Brave Warrior Advisors Valeant Pharmaceuticals International Inc transactions over time

Total transactions:
13
New positions:
1
Sold out:
1
Added:
3
Reduced:
8
Held since:
2013 Q2 or earlier
Held for:
12+ quarters
Latest activity:
2016 Q2
Glenn Greenberg has been an institutional investor in Valeant Pharmaceuticals International Inc (VRX) since at least 2013 Q2. According to 2026 Q1 report, Glenn Greenberg doesn't hold any shares. In our earliest available record from 2013 Q2, Brave Warrior Advisors held about 6.66M shares of VRX. Since at least 2013 Q2, Brave Warrior Advisors has made 12 more transactions in this position.

When did Glenn Greenberg exit their VRX position?

Glenn Greenberg no longer holds Valeant Pharmaceuticals International Inc (VRX). They sold off their entire position in 2016 Q2, closing out an investment that began in 2013 Q2.

Estimated cost basis*

Weighted AVG buy price:
$92.45
Weighted AVG sell price:
$56.73

VRX transactions history by Brave Warrior Advisors

13 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2016 Q2
0.00%
$26.30
-100% (-2,034,281)
2016 Q1
2.61%
$26.30
-67.46% (-4,218,050)
2015 Q4
25.22%
$101.65
+12.09% (+674,439)
2015 Q3
31.62%
$178.38
-2.16% (-123,118)
2015 Q2
36.57%
$222.15
-2.99% (-176,006)
2015 Q1
35.64%
$198.62
-4.07% (-249,593)
2014 Q4
30.53%
$143.11
-6.98% (-459,973)
2014 Q3
32.02%
$131.20
+8.86% (+536,140)
2014 Q2
30.78%
$126.12
+8.19% (+457,884)
2014 Q1
29.80%
$131.83
-8.52% (-520,669)
2013 Q4
29.38%
$117.40
-7.00% (-460,362)
2013 Q3
30.77%
$104.33
-1.26% (-83,862)
2013 Q2
26.53%
$86.08
new or own*
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.